LoQus23
1 known investors
LoQus23 Therapeutics develops small molecule somatic expansion inhibitors aimed at stopping DNA instability to slow neurodegeneration. Its approach targets Huntington's Disease and other triplet repeat expansion diseases.
1 known investors
LoQus23 Therapeutics develops small molecule somatic expansion inhibitors aimed at stopping DNA instability to slow neurodegeneration. Its approach targets Huntington's Disease and other triplet repeat expansion diseases.